Tilray (TLRY) Expected to Announce Quarterly Earnings on Tuesday

Tilray (NASDAQ:TLRY - Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, April 8th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $213.38 million for the quarter. Tilray has set its FY 2025 guidance at EPS.Seeking Stability? These 3 Stocks Offer Strong PotentialTilray (NASDAQ:TLRY - Get Free Report) last posted its earnings results on Friday, January 10th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.07). The company had revenue of $210.90 million during the quarter, compared to analyst estimates of $216.34 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. The firm's quarterly revenue was up 8.7% compared to the same quarter last year. On average, analysts expect Tilray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Tilray Trading Down 0.8 %Shares of TLRY stock opened at $0.66 on Tuesday. The company has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.25. The firm has a market cap of $616.51 million, a PE ratio of -2.19 and a beta of 2.13. Tilray has a 1-year low of $0.58 and a 1-year high of $2.97. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.54 and a quick ratio of 1.58. Analyst Upgrades and DowngradesCannabis Stocks: Game-Changing Catalyst for the Sector?Separately, Canaccord Genuity Group lifted their target price on shares of Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a report on Monday, January 13th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $2.70.Read Our Latest Stock Analysis on TLRYTilray Company Profile (Get Free Report)Tilray’s Q3 Earnings Reveal Growth Despite ChallengesTilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada. Read MoreFive stocks we like better than TilrayMost Volatile Stocks, What Investors Need to Know3 Buyable Stocks With Solid Bottoms Ready to ReboundShould You Add These Warren Buffett Stocks to Your Portfolio?Advantage+ Shopping: Meta's Fast Growing $20 Billion AI-Ads StarWhat Investors Need to Know About Upcoming IPOsRobotaxi News: What Tesla and Lyft Headlines Mean for SharesThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Tilray Right Now?Before you consider Tilray, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here